Recently, albumin failed to demonstrate efficacy in the prevention of complications of cirrhosis (HE, gastrointestinal bleeding, hyponatremia, renal failure, and bacterial infections) in patients on the liver-transplant waiting list [9]. Here, ALB is linked to hereditary elliptocytosis.